DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Plimack ER, Motzer RJ, Escudier B. et al.
Two-Year Efficacy and Safety Update: Phase III CheckMate 025 Study of Nivolumab vs Everolimus in Patients With Advanced Renal Cell Carcinoma (aRCC).
Abstracts from the NCRI Cancer Conferences 2016
We do not assume any responsibility for the contents of the web pages of other providers.